H
Heinrich Bodenstein
Researcher at University of Münster
Publications - 32
Citations - 2246
Heinrich Bodenstein is an academic researcher from University of Münster. The author has contributed to research in topics: Mitoxantrone & Chemotherapy. The author has an hindex of 17, co-authored 32 publications receiving 2120 citations.
Papers
More filters
Journal ArticleDOI
Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group
Udo Vanhoefer,Philippe Rougier,Hansjochen Wilke,Michel Ducreux,A. J. Lacave,Eric Van Cutsem,Manfred Planker,José Guimaraes Dos Santos,Pascal Piedbois,Bernard Paillot,Heinrich Bodenstein,Hans-Jochen Schmoll,Harry Bleiberg,Bernard Nordlinger,Marie-Laure Couvreur,Benoit Baron,Jacques Wils +16 more
TL;DR: All three investigated regimens demonstrate modest clinical efficacy and should not be regarded as standard treatment for advanced gastric cancer, with neutropenia being the major toxicity for all three regimens.
Journal ArticleDOI
Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92.
Peter Koch,Francisco del Valle,Wolfgang E. Berdel,Normann Willich,Berthold Reers,Wolfgang Hiddemann,Bernward Grothaus-Pinke,Gabriele Reinartz,Jens Brockmann,Altfried Temmesfeld,Rudolf Schmitz,C. Rübe,Andreas Probst,Gert Jaenke,Heinrich Bodenstein,Arved Junker,Christiane Pott,Jürgen Schultze,Achim Heinecke,R. Parwaresch,M. Tiemann +20 more
TL;DR: In this paper, a study was conducted to obtain anatomic and histologic distribution, clinical features, and treatment results in patients with primary gastrointestinal non-Hodgkin's lymphomas (PGI NHL).
Journal ArticleDOI
Primary Gastrointestinal Non-Hodgkin’s Lymphoma: II. Combined Surgical and Conservative or Conservative Management Only in Localized Gastric Lymphoma—Results of the Prospective German Multicenter Study GIT NHL 01/92
Peter Koch,Francisco del Valle,Wolfgang E. Berdel,Normann Willich,Berthold Reers,Wolfgang Hiddemann,Bernward Grothaus-Pinke,Gabriele Reinartz,Jens Brockmann,Altfried Temmesfeld,Rudolf Schmitz,C. Rübe,Andreas Probst,Gert Jaenke,Heinrich Bodenstein,Arved Junker,Christiane Pott,Jürgen Schultze,Achim Heinecke,R. Parwaresch,M. Tiemann +20 more
TL;DR: Although the study was not randomized, a stomach-conserving approach may be favored and complete resection of the tumor (R0) was prognostic for the overall survival as compared with incomplete resection.
Journal ArticleDOI
Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System
Christoph Röllig,Martin Bornhäuser,Christian Thiede,Franziska Taube,Michael S. Kramer,Brigitte Mohr,Walter E. Aulitzky,Heinrich Bodenstein,Hans-Joachim Tischler,Reingard Stuhlmann,Ulrich Schuler,Friedrich Stölzel,Malte von Bonin,Hannes Wandt,Kerstin Schäfer-Eckart,Markus Schaich,Gerhard Ehninger +16 more
TL;DR: In younger patients with AML, the ELN classification seems to be the best available framework for prognostic estimations to date, and caution is advised concerning its use for prospective treatment allocation before it has been prospectively validated.
Journal ArticleDOI
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial
Christoph Röllig,Christian Thiede,Martin Gramatzki,Walter E. Aulitzky,Heinrich Bodenstein,Martin Bornhäuser,Uwe Platzbecker,Reingard Stuhlmann,Ulrich Schuler,Silke Soucek,Michael S. Kramer,Brigitte Mohr,Uta Oelschlaegel,Friedrich Stölzel,Malte von Bonin,Martin Wermke,Hannes Wandt,Gerhard Ehninger,Markus Schaich +18 more
TL;DR: An analysis of prognostic factors derived from a trial in patients with acute myeloid leukemia older than 60 years revealed that karyotype, age, NPM1 mutation status, white blood cell count, lactate dehydrogenase, and CD34 expression were of independent prognostic significance for OS.